Aquestive Therapeutics (NASDAQ:AQST) Stock Price Down 13%

Aquestive Therapeutics Inc (NASDAQ:AQST)’s stock price was down 13% during trading on Thursday . The stock traded as low as $6.50 and last traded at $6.70, approximately 1,708,160 shares changed hands during trading. An increase of 672% from the average daily volume of 221,385 shares. The stock had previously closed at $7.70.

A number of brokerages have recently weighed in on AQST. Zacks Investment Research upgraded Aquestive Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a research report on Monday, November 11th. HC Wainwright restated a “buy” rating and set a $14.00 price objective (up previously from $12.00) on shares of Aquestive Therapeutics in a research report on Monday, December 2nd. Wedbush restated a “buy” rating and set a $37.00 price objective on shares of Aquestive Therapeutics in a research report on Monday, December 2nd. Finally, ValuEngine upgraded Aquestive Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday. Six research analysts have rated the stock with a buy rating, Aquestive Therapeutics presently has an average rating of “Buy” and a consensus target price of $18.40.

The firm’s 50-day moving average price is $5.96 and its 200 day moving average price is $4.33. The firm has a market cap of $167.79 million, a P/E ratio of -2.39 and a beta of 2.76.

A number of large investors have recently modified their holdings of the stock. Meeder Asset Management Inc. grew its position in Aquestive Therapeutics by 460.2% in the 3rd quarter. Meeder Asset Management Inc. now owns 8,129 shares of the company’s stock worth $26,000 after purchasing an additional 6,678 shares during the last quarter. Russell Investments Group Ltd. bought a new position in Aquestive Therapeutics in the 3rd quarter worth approximately $46,000. Morgan Stanley grew its holdings in Aquestive Therapeutics by 706.1% in the 2nd quarter. Morgan Stanley now owns 17,323 shares of the company’s stock worth $73,000 after buying an additional 15,174 shares in the last quarter. JPMorgan Chase & Co. increased its position in Aquestive Therapeutics by 728.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 22,761 shares of the company’s stock valued at $93,000 after acquiring an additional 20,014 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new stake in Aquestive Therapeutics in the 2nd quarter valued at approximately $105,000. Hedge funds and other institutional investors own 62.69% of the company’s stock.

Aquestive Therapeutics Company Profile (NASDAQ:AQST)

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.

Recommended Story: What is an Initial Coin Offering (ICO)?

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.